INFLARX
InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. In April 2018, InflaRx conducted a USD 117 million total gross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.
INFLARX
Social Links:
Industry:
Health Care Medical Pharmaceutical Therapeutics
Founded:
2007-12-01
Address:
Jena, Thuringen, Germany
Country:
Germany
Website Url:
http://www.inflarx.de
Total Employee:
11+
Status:
Active
Contact:
+49 (0)3641 508 180
Total Funding:
214.83 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Apache Nginx Microsoft Exchange Online Office 365 Mail
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Altamira Therapeutics
Altamira Therapeutics develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Employees Featured
Founder
Stock Details
Investors List
Federal Ministry of Health
Federal Ministry of Health investment in Grant - InflaRx
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - InflaRx
Cormorant Asset Management
Cormorant Asset Management investment in Series D - InflaRx
RA Capital Management
RA Capital Management investment in Series D - InflaRx
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series D - InflaRx
Staidson Hongkong Investment
Staidson Hongkong Investment investment in Series C - InflaRx
bm-t beteiligungsmanagement thuringen
bm-t beteiligungsmanagement thuringen investment in Series B - InflaRx
Affentranger Associates
Affentranger Associates investment in Series A - InflaRx
bm-t beteiligungsmanagement thuringen
bm-t beteiligungsmanagement thuringen investment in Seed Round - InflaRx
Affentranger Associates
Affentranger Associates investment in Seed Round - InflaRx
Official Site Inspections
http://www.inflarx.de Semrush global rank: 4.18 M Semrush visits lastest month: 2.84 K
- Host name: 85.215.36.174
- IP address: 85.215.36.174
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "InflaRx"
Company History - inflarx.de
InflaRx was therefore able to build an in-house team with vast expertise in the acute care and inflammatory disease field. Simultaneously, CSO, Renfeng Guo expanded the company’s …See details»
InflaRx - LinkedIn
Inflarx.de 27 Like Comment Share InflaRx 2,812 followers 2mo ... InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal …See details»
InflaRx Profile | The Scientist
InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize …See details»
InflaRx - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +49 (0)3641 508 180 InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of …See details»
InflaRx Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 InflaRx has 4 employees across 2 locations and €166 k in annual revenue in FY 2024. See insights on InflaRx including office locations, competitors, revenue, financials, …See details»
InflaRx GmbH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for InflaRx GmbH of Jena, Thüringen. Get the latest business insights from Dun & Bradstreet.See details»
InflaRx Company Profile | Management and Employees List
[email protected]: Your Questions, Our Answers Get Free Access to InflaRx Contacts Info. What is InflaRx revenue? InflaRx revenue is $106 K. How many employees does InflaRx have? …See details»
Controlling - inflarx.de
Jena, Germany, May 7, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceuti ... May 07, 2025 10 Minutes InflaRx to Report First Quarter 2025 Results on May 7, 2025See details»
InflaRx - Overview, News & Similar companies | ZoomInfo.com
May 8, 2019 InflaRx contact info: Phone number: +49 493641508180 Website: www.inflarx.de What does InflaRx do? InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company …See details»
InflaRx (IFRX) Company Profile & Description - Stock Analysis
Nov 8, 2017 InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an …See details»
InflaRx Announces Closing of $30 Million Public Offering of
Feb 18, 2025 InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has …See details»
Leadership Team - inflarx.de
Contact Jena. InflaRx N.V. / InflaRx GmbH Winzerlaer Str. 2 07745 Jena +49 3641 508 180 [email protected] InflaRx on LinkedinSee details»
InflaRx GmbH Company Profile | Planegg, Bayern, Germany
Find company research, competitor information, contact details & financial data for InflaRx GmbH of Planegg, Bayern. Get the latest business insights from Dun & Bradstreet.See details»
CORPORATE PRESENTATION - inflarx.de
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, “InflaRx”). InflaRx (Nasdaq: IFRX) is a biotechnology company …See details»
Press Release - inflarx.de
Jena, Germany, February 18, 2025 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the …See details»
Team - inflarx.de
Contact Jena. InflaRx N.V. / InflaRx GmbH Winzerlaer Str. 2 07745 Jena +49 3641 508 180 [email protected] InflaRx on LinkedinSee details»
Press Release - inflarx.de
1 day ago Jena, Germany, May 22, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, …See details»
InflaRx: Zulassung! - DER AKTIONÄR
Jan 16, 2025 Die deutsche Biotech-Gesellschaft InflaRx kann einen wichtigen Meilenstein verbuchen. Denn die Europäische Kommission hat die Zulassung für Gohibic (Vilobelimab) zur …See details»
InflaRx: Diesen deutschen Biotech-Senkrechtstarter ... - DER …
Apr 27, 2019 Können die Studiendaten im laufenden Quartal überzeugen, hat InflaRx das Potenzial, zu einem ganz Großen der deutschen Biotech-Szene zu werden. Risikobereite …See details»
Börse Express - InflaRx Aktie: Zwischen Hoffnung und Risiko
Apr 24, 2025 Neue InflaRx-Analyse vom 25. April liefert die Antwort: Die neusten InflaRx-Zahlen sprechen eine klare Sprache: Dringender Handlungsbedarf für InflaRx-Aktionäre.See details»